These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Yamaguchi H, Shimizu M, Ban S, Koyama I, Hatori T, Fujita I, Yamamoto M, Kawamura S, Kobayashi M, Ishida K, Morikawa T, Motoi F, Unno M, Kanno A, Satoh K, Shimosegawa T, Orikasa H, Watanabe T, Nishimura K, Ebihara Y, Koike N, Furukawa T. Am J Surg Pathol; 2009 Aug; 33(8):1164-72. PubMed ID: 19440145 [Abstract] [Full Text] [Related]
43. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization. Dancer J, Takei H, Ro JY, Lowery-Nordberg M. Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361 [Abstract] [Full Text] [Related]
44. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. Clin Cancer Res; 2007 Dec 15; 13(24):7380-7. PubMed ID: 18094420 [Abstract] [Full Text] [Related]
45. Cripto-1 overexpression is involved in the tumorigenesis of gastric-type and pancreatobiliary-type intraductal papillary mucinous neoplasms of the pancreas. Hong SP, Lee EK, Park JY, Jeon TJ, Bang S, Park S, Chung JB, Lee WJ, Kim H, Song SY. Oncol Rep; 2009 Jan 15; 21(1):19-24. PubMed ID: 19082438 [Abstract] [Full Text] [Related]
46. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. Ohuchida K, Mizumoto K, Miyasaka Y, Yu J, Cui L, Yamaguchi H, Toma H, Takahata S, Sato N, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. J Pathol; 2007 Nov 15; 213(3):275-82. PubMed ID: 17940995 [Abstract] [Full Text] [Related]
47. Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution. Bergmann F, Esposito I, Michalski CW, Herpel E, Friess H, Schirmacher P. Am J Surg Pathol; 2007 Dec 15; 31(12):1919-25. PubMed ID: 18043049 [Abstract] [Full Text] [Related]
50. Immunoreactivity for hepatocyte paraffin 1 antibody in hepatoid adenocarcinomas of the gastrointestinal tract. Maitra A, Murakata LA, Albores-Saavedra J. Am J Clin Pathol; 2001 May 15; 115(5):689-94. PubMed ID: 11345832 [Abstract] [Full Text] [Related]
53. Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma. Hara H, Suda K. Am J Clin Pathol; 2008 Jan 15; 129(1):115-29. PubMed ID: 18089497 [Abstract] [Full Text] [Related]
54. Pancreatic lipase is a useful phenotypic marker of intrahepatic large and septal bile ducts, peribiliary glands, and their malignant counterparts. Terada T, Nakanuma Y. Mod Pathol; 1993 Jul 15; 6(4):419-26. PubMed ID: 8415585 [Abstract] [Full Text] [Related]
55. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC, van de Rijn M, Brooks JD. Am J Surg Pathol; 2007 May 15; 31(5):673-80. PubMed ID: 17460449 [Abstract] [Full Text] [Related]
56. Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms. Vlasoff DM, Baschinsky DY, Frankel WL. Appl Immunohistochem Mol Morphol; 2002 Jun 15; 10(2):147-51. PubMed ID: 12051633 [Abstract] [Full Text] [Related]